MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-03-2023
Axcella Health Total Current Liabilities 2011-2026 | AXLA
Annual Total Current Liabilities Axcella Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.1 M | 10.2 M | 7.78 M | 8.36 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.1 M | 7.78 M | 10.1 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADMA Biologics
ADMA
|
69.5 M | $ 16.54 | 0.98 % | $ 3.94 B |  USA |
 |
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
324 M | $ 19.86 | - | $ 2.51 B | USA |
 |
Aptorum Group Limited
APM
|
4.34 M | $ 0.83 | 4.19 % | $ 4.53 M |  China |
 |
AbCellera Biologics
ABCL
|
64.3 M | $ 3.63 | -2.16 % | $ 1.08 B |  Canada |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
194 M | $ 76.53 | 0.57 % | $ 1.48 B | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
18.7 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
379 M | $ 164.08 | 0.02 % | $ 8.16 B | USA |
 |
Champions Oncology
CSBR
|
23.9 M | $ 6.0 | - | $ 82 M | USA |
 |
BridgeBio Pharma
BBIO
|
288 M | $ 66.54 | 3.11 % | $ 12.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
8.98 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
759 M | $ 60.43 | 3.25 % | $ 11.6 B | USA |
 |
Cabaletta Bio
CABA
|
16 M | $ 3.43 | 5.54 % | $ 4.01 M | USA |
 |
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
256 M | $ 3.2 | 0.63 % | $ 1.15 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M |  Israel |
 |
Capricor Therapeutics
CAPR
|
31.3 M | $ 25.5 | -1.32 % | $ 683 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
82.2 M | $ 28.19 | -1.02 % | $ 1.63 B | USA |
 |
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | USA |